Nanobiotix seeks to boost cancer care with nanoparticle-radiotherapy combo
Increasingly, pharma and biotech companies are looking towards personalized medicine to guide their portfolios, developing therapies designed to address the needs of individual patient populations....
View ArticleNanobiotix’s nanoparticle-immunotherapy trial wins FDA approval
Nanobiotix (EMA:NANO) said today that the FDA has approved its IND application for a cancer trial combining its radiotherapy-activated nanoparticle tech with an anti-PD1 antibody. The Phase I/II trial...
View ArticleNanobiotix inks $47m financing to support nanomedicine development
Nanobiotix (PAR:NANO.PA) inked a non-dilutive financial deal with the European Investment Bank last week to support the development of its nanoparticle-based cancer therapies. The Paris, France-based...
View ArticleNanobiotix reels in $18.5m tranche from European Investment Bank
Nanobiotix (PAR:NANO.PA) received €16 million ($18.5 million) in the first tranche of a previously-announced non-dilutive loan from the European Investment Bank. The five-year funding deal is designed...
View ArticleFDA clears Nanobiotix to start cancer treatment trial
Nanobiotix (PAR:NANO.PA) announced that the FDA designated its cancer treatment trial with the University of Texas MD Anderson Cancer Center as “safe to proceed.” The trial, co-developed by Nanobiotix...
View ArticleNanobiotix seeks to boost cancer care with nanoparticle-radiotherapy combo
Increasingly, pharma and biotech companies are looking towards personalized medicine to guide their portfolios, developing therapies designed to address the needs of individual patient populations....
View ArticleNanobiotix’s nanoparticle-immunotherapy trial wins FDA approval
Nanobiotix (EMA:NANO) said today that the FDA has approved its IND application for a cancer trial combining its radiotherapy-activated nanoparticle tech with an anti-PD1 antibody. The Phase I/II trial...
View Article
More Pages to Explore .....